Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
NCT03311126 · University of Wisconsin, Madison · PHASE2 · terminated · last registry update 2024-10-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | – | Registry record, University of Wisconsin, Madison |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MS4A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-23Phase 3 first posted: TG Therapeutics, Inc., Ublituximab + Placebo (NCT07220252)
- 2025-10-08Phase 3 first posted: TG Therapeutics, Inc., Ublituximab + Ublituximab (NCT07211633)
- 2025-09-23Phase 3 first posted: University Hospital, Montpellier, Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) + Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) (NCT07189325)
- 2025-09-17Also stopped (withdrawn): M.D. Anderson Cancer Center, Glofitamab (NCT06670105)
- 2025-09-15Results posted on the registry: University of California, San Diego, GA101 + Ibrutinib (NCT02315768)
- 2025-09-09Phase 3 first posted: Radboud University Medical Center, Obinutuzumab administration (NCT07163611)
- 2025-08-12Results posted on the registry: Dana-Farber Cancer Institute, Venetoclax + Obinutuzumab (NCT03580928)
- 2025-08-06Results posted on the registry: Emory University, Bendamustine + Obinutuzumab (NCT03872180)
- 2025-07-22Also stopped (terminated): University of Washington, Pembrolizumab + Rituximab (NCT03401853)
- 2025-07-09Also stopped (terminated): Mayo Clinic, Rituximab (NCT02320292)
- 2025-06-24Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Obinutuzumab (NCT01995669)
- 2025-06-06Results posted on the registry: Weill Medical College of Cornell University, Acalabrutinib + Lenalidomide (NCT03863184)
- 2025-05-22Results posted on the registry: Hoffmann-La Roche, Ocrelizumab (NCT04998812)
- 2025-05-14Phase 3 first posted: BeOne Medicines, BGB-16673 + Bendamustine (NCT06970743)
- 2025-04-24Phase 3 first posted: BeOne Medicines, Sonrotoclax + Obinutuzumab (NCT06943872)
- 2025-04-20Results posted on the registry: National Cancer Institute (NCI), Obinutuzumab + Prednisone (NCT05211336)
- 2025-04-18Results posted on the registry: University of Washington, Pembrolizumab + Rituximab (NCT03401853)
- 2025-04-17Results posted on the registry: Hoffmann-La Roche, Obinutuzumab + Venetoclax (NCT04285567)
- 2025-04-16Results posted on the registry: Hoffmann-La Roche, Ocrelizumab (NCT04998851)
- 2025-03-12Results posted on the registry: Dana-Farber Cancer Institute, Obinutuzumab + Placebo (NCT02867384)
- 2025-02-27Results posted on the registry: Jennifer R. Brown, MD, PhD, Acalabrutinib + Umbralisib (NCT04624633)
- 2025-02-26Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib oral treatment + Ocrelizumab (NCT06846281)
- 2025-02-26Phase 3 first posted: Sandoz, CYB704 + Ocrevus-EU (NCT06847724)
- 2025-01-17Phase 3 first posted: Huashan Hospital, Obinutuzumab + CTX combined with Glucocorticoids (NCT06781944)
- 2024-11-22Phase 3 first posted: Amgen, Ocrelizumab (US) + Ocrelizumab (EU) (NCT06700343)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision